This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.
Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale
by Zacks Equity Research
Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.
Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study
by Zacks Equity Research
Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.
Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals
by Zacks Equity Research
Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.
Roche's (RHHBY) Vabysmo Positive in Late-Stage RVO Studies
by Zacks Equity Research
Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III studies for retinal vein occlusion.
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
by Zacks Equity Research
Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.
Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag
by Zacks Equity Research
FDA grants the Orphan Drug designation to Baudax (BXRX) for its lead pipeline candidate, TI-168, to treat Hemophilia A patients with inhibitors.
PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024
by Zacks Equity Research
PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
by Zacks Equity Research
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study
by Zacks Equity Research
Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.
Roche's (RHHBY) Application for PNH Drug Accepted by FDA
by Zacks Equity Research
Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.
AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
by Zacks Equity Research
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.
Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates
by Kinjel Shah
J&J (JNJ) updates its financial guidance for 2023 after the final separation of Kenvue. Pfizer, BioNTech, Merck and AbbVie announce regulatory developments.
Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal
by Zacks Equity Research
Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.
Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD
by Zacks Equity Research
Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
by Zacks Equity Research
Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.
The Zacks Analyst Blog Highlights Alphabet, Roche Holding, Honeywell International, IBM and The Goldman Sachs
by Zacks Equity Research
Alphabet, Roche Holding, Honeywell International, IBM and The Goldman Sachs are part of the Zacks top Analyst Blog.
Top Stock Reports for Alphabet, Roche & Honeywell International
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Roche Holding AG (RHHBY) and Honeywell International Inc. (HON).
Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation
by Kinjel Shah
FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.
Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak
by Zacks Equity Research
Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.
Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study
by Zacks Equity Research
Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
by Zacks Equity Research
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
by Zacks Equity Research
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.